1. Pink Sheet
  2. >>Geography
  3. >>International

New ePortal To Simplify Processing & Tracking Of WHO Prequalification Applications

 
• By Neena Brizmohun

The World Health Organization, whose prequalification team received over 1,000 applications last year, is launching an electronic portal that should make it easier for manufacturers and regulators to keep track of submissions.

Users of the portal will be able to see where their applications sit within a specific prequalification process • Source: Shutterstock

The World Health Organization is planning to launch an electronic prequalification (PQ) system (ePQS) portal that will allow regulators and pharma and medtech companies to track prequalification products, applications and inspections more efficiently and in real time.

The new portal, which is due to go live on 1 January 2024, will be used to process PQ information...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.

Alzheimer’s Drug Leqembi May Be On Course To India, Kisunla In The Wings

 
• By Anju Ghangurde

Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.